
WHAT IS CLAIMED IS:

1. Use of an effective amount of a compound in the manufacture for a medicament for treating breast cancer in a subject, wherein the compound is Compound (A), or a pharmaceutically acceptable salt thereof, has the structure:



(A); and

wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERα), wherein the mutation is selected from the group consisting of: Y537S and L536P.

2. The use of Claim 1, wherein the breast cancer is ER positive breast cancer.

3. The use of Claim 1, wherein the breast cancer is ER positive/HER2-negative breast cancer.

4. The use of any one of Claims 1-3, wherein the breast cancer is local breast cancer, metastatic breast cancer and recurrent breast cancer.

5. The use of any one of Claims 1-4, wherein the subject has been previously treated with an endocrine therapy.

6. The use of Claim 5, wherein the treatment was with a selective ER modulator (SERM).

7. The use of Claim 6, wherein the selective ER modulator is selected from the group consisting of tamoxifen, raloxifene, ospemifene, bazedoxifene, toremifene and lasofoxifene.

8. The use of Claim 5, wherein the treatment was with a selective ER degrader (SERD).

9. The use of Claim 8, wherein the selective ER degrader is selected from the group consisting of fulvestrant, elacestrant, (E)-3-[3,5-Difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid, (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-

en-1-yl)phenyl)acrylic acid, (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid, (E)-3-(4-((2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid, (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid and 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol.

10. The use of Claim 5, wherein the treatment was with an aromatase inhibitor.

11. The use of Claim 10, wherein the aromatase inhibitor is a steroidal aromatase inhibitor.

12. The use of Claim 10, wherein the aromatase inhibitor is a non-steroidal aromatase inhibitor.

13. The use of Claim 10, wherein the aromatase inhibitor is selected from the group consisting of exemestane, testolactone, anastazole and letrazole.

14. The use of any one of Claim 1-13, wherein the subject is a woman.

15. The use of Claim 14, wherein the subject is a premenopausal woman.

16. The use of Claim 14, wherein the subject is a perimenopausal woman.

17. The use of Claim 14, wherein the subject is a menopausal woman.

18. The use of Claim 14, wherein the subject is a postmenopausal woman.

19. The use of any one of Claim 1-13, wherein the subject is a man.

20. The use of any one of Claim 1-19, wherein the subject has a serum estradiol level in the range of >15 pg/mL to 350 pg/mL.

21. The use of any one of Claim 1-19, wherein the subject has a serum estradiol level $\leq$ 15 pg/mL.

22. The use of any one of Claims 1-21, wherein the mutation is Y537S.

55981823